Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Cytek Biosciences (Nasdaq: CTKB) announced it will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026.
Rhea-AI Summary
Cytek Biosciences (Nasdaq: CTKB) announced it will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will host a webcast conference call at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss results, business developments and outlook, accessible via the Investors section of its website at investors.cytekbio.com.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CTKB
In the Jul 23 session, CTKB gained 0.44%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Reporting period
- Second quarter 2026
- Financial results announcement
- Results date
- August 5, 2026
- After market close
- Pacific webcast time
- 1:30 p.m. Pacific Time
- Corresponding conference call
- Eastern webcast time
- 4:30 p.m. Eastern Time
- Corresponding conference call
Previous Earnings date Reports
-
Announced first-quarter results date and webcast timing
-
Announced fourth-quarter and full-year results date
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREMONT, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the second quarter of 2026 after market close on Wednesday, August 5, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution for information about the company, its products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Certain information disseminated through these channels may be material to investors, and Cytek may use these channels to disseminate such information in accordance with Regulation FD and other applicable disclosure requirements. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Mark Meehan
Cytek Biosciences
mmeehan@cytekbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.